Papers/PMID:36121807
Comparative efficacy and safety of caffeine citrate and aminophylline in treating apnea of prematurity: A systematic review and meta-analysis.
PloS one2022The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
caffeine — decreases adverse reaction incidence (unstandardised)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“The analysis found that compared with aminophylline, infants in the caffeine group had a lower chance of developing total adverse effects (OR 0.41, 95%CI: 0.17–0.97, P = 0.042).”
Quoted verbatim from Comparative efficacy and safety of caffeine citrate and aminophylline in treating apnea of prematurity: A systematic review and meta-analysis.. - Study
- meta-analysis
- Population
- Preterm infants (<37 weeks gestation) with apnea of prematurity; caffeine citrate against an ACTIVE COMPARATOR (aminophylline), not placebo; safety outcome pooled from 4 of the 10 included studies.
Effect 0.41 odds ratio, 95% CI 0.17 to 0.97
Comparative efficacy and safety of caffeine citrate and aminophylline in treating apnea of prematurity: A systematic review and meta-analysis.2022PMID:36121807Permalink